Table 4.
The changes of variables at different time points after treatment with mirabegron 25 mg daily in patients who were followed up to 3 months
| Baseline | 1 month | 3 months |
P Baseline to 1 month |
P 1-3 months |
|
|---|---|---|---|---|---|
| Nocturia/day | 3.3 ± 1.3 | 3.3 ± 1.3 | 3.2 ± 1.2 | 0.802 | 1.000 |
| Qmax (mL/s) | 12.0 ± 8.3 | 12.7 ± 8.0 | 12.5 ± 8.4 | 0.074 | 0.979 |
| Vol (mL) | 188 ± 138 | 203 ± 139 | 195 ± 150 | 0.094 | 0.634 |
| PVR (mL) | 62.4 ± 80.2 | 44.5 ± 52.3 | 48.7 ± 60.1 | 0.000 | 0.558 |
| IPSS_V | 5.4 ± 5.2 | 4.4 ± 4.8 | 3.7 ± 4.4 | 0.002 | 0.094 |
| IPSS_S | 4.3 ± 2.2 | 4.3 ± 2.3 | 4.1 ± 2.3 | 0.861 | 0.826 |
| IPSS_T | 9.8 ± 6.1 | 8.6 ± 5.6 | 7.8 ± 5.5 | 0.006 | 0.124 |
| QoL-I | 2.8 ± 1.2 | 2.4 ± 0.9 | 2.0 ± 1.0 | 0.000 | 0.002 |
| OABSS | 3.0 ± 0.9 | 4.1 ± 2.5 | 4.1 ± 2.4 | 0.000 | 0.929 |
| USS | 0.0 ± 0.1 | 0.8 ± 1.5 | 0.8 ± 1.5 | 0.000 | 0.785 |
| PPBC | 2.5 ± 1.7 | 2.0 ± 1.4 | 1.6 ± 1.3 | 0.000 | 0.029 |
| GRA | 0.0 ± 0.0 | 1.0 ± 1.4 | 1.6 ± 1.4 | 0.000 | 0.000 |
IPSS: International Prostate Symptom Score, IPSS-V: IPSS voiding subscore, IPSS-S: IPSS storage subscore, IPSS-T: IPSS total score, QoL-I: Quality of life index, OABSS: Overactive Bladder Symptom Score, USS: Urgency Severity Scale, PPBC: Patient Perception of Bladder Condition, GRA: Global response assessment, Vol: Voided volume, Qmax: Maximum flow rate